PRIDE Complex Secondary to Cetuximab in Nasopharyngeal Carcinoma

Rohit Kothari, MD1* | Karthi Kishore, MBBS2 | Anuj Bhatnagar, MD, DNB3

*Correspondence: Rohit Kothari, MD
Address: 1Assistant Professor, Dermatology, Command Hospital Air Force, Bengaluru, India; 2Junior Resident, Dermatology, Command Hospital Air Force, Bengaluru, India; 3Professor, Dermatology, Command Hospital Air Force, Bengaluru, India

e-mail rohitkothari3422@gmail.com

Received: 20 September 2022; Accepted: 30 September 2022

Copyright: © 2022 Kothari R. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Clinical Image

A 54-years-old male, case of Nasopharyngeal carcinoma (T1N2M0) was given six monthly doses of Injection Cetuximab. He presented to dermatology clinic with paronychia of left thumb, middle and ring finger, subungual hyperkeratosis (Panel A) and recurrent crops of papulopustular lesions over scalp, face (Panel B), trunk and extremities associated with dryness (white arrow) (Panel C) and itching for last six months. He also complained of excessive hair fall. He was diagnosed as PRIDE complex (Papulopustules and/or paronychia, Regulatory abnormalities of hair-growth, Itching, Dryness) secondary to Cetuximab and treated with oral Doxycycline, topical Clindamycin, tretinoin and emollients. He was in remission at last follow-up after one month.
Conflict of Interest: None for all authors

Data Availability Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Acknowledgement: The patient in this manuscript has given written informed consent to the publication of his case details and photographs.

Author Contribution Statement: The manuscript has been read and approved by all the authors and each author believes that the manuscript represents honest work.